Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Abnormalities 1Sezary Syndrome 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Saline Solution 1Ringer's Lactate 1Ofloxacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Ear Neoplasms × Saline Solution × Clear all
NCT00584155 2015-05-27

Protection From Cisplatin Ototoxicity by Lactated Ringers

University of Oklahoma

Phase 1 Withdrawn

Ear Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡